|
|
 |
|
Viewing report
|
|
|
|
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
GBI Research, Sep 2011, Pages: 97
“Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia” gives a robust idea about the patient recruitment status by geography, by sponsor company, and by year for all the major CNS indications. Furthermore, the report provides profiles of prevalence with forecast data up to 2017 for all the major CNS indications. The major indications covered in the report are Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
The authors found that the highest number of trials was conducted in schizophrenia, which corresponds to the highest levels of patient recruitment for the period 2000-2009, for trials which were industry sponsored with completed status. Within the CNS market, the Alzheimer’s and Parkinson’s disease sectors have been identified as the fastest growing sectors. In terms of reimbursement, countries like Germany, France and Canada have been identified as having the most robust and patient-friendly regulations for CNS therapeutics. The central nervous system is a complex and sophisticated system that regulates and co-ordinates the basic functions and activities of the human body. The human central nervous system consists of the brain, spinal cord and the neural network connecting these to the body.
Owing to its complexity and intricacies, the CNS is vulnerable to various complications and disorders. Disorders within the CNS are primarily associated with the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system and the neuromuscular network, including the muscles. A substantial portion of CNS disorders can be grouped under neurodegenerative disorders such as Alzheimer’s, which are primarily associated with the deterioration or break down of cerebral and spinal cells. Other diseases associated with the CNS include psychiatric or mental disorders such as Attention Deficit Hyperactivity Disorder (ADHD). These disorders are related to individuals’ psychological or behavioral patterns, and are thought to cause distress or disabilities that are not expected as part of normal development. Other major neurological disorders include epilepsy, pain and sleep related complications such as migraine and insomnia.
Scope
The report analyzes the clinical trial recruitment trends of the pharmaceutical companies for various neurology trials. Its scope includes -
- Insight on Clinical Trials conducted for major indications of neurology such as Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression from 2000-2009.
- The status of patient recruitment by geography, Sponsor Company, year and stage of development.
- Analysis of the average number of patients recruited per trial for major indications per year.
- Analysis of the average number of patients recruited per trial for major indications by stage of development.
- The prevalence population in India, China and Brazil for all major indications from 2010-2017.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Identify and understand the status of clinical trials conducted for major neurology indications from 2000-2009.
- Build understanding of patient recruitment status by geography, Sponsor Company, year and stage of development.
- Identify the prevalence population for the major indications up to 2017.
- Identify the average number of patients recruited by stage of development and across years for all major indications.
- Identify the indication in which the highest number of trials is conducted and the highest number of patients recruited.
|
|
|
|
